In our study of young women with breast cancer, although there were no apparent differences in survival outcomes between BRCA1 and BRCA2 carriers, a distinct pattern of DFS events over time was observed with a peak among BRCA1 carriers in the first 2 years and a constant risk over time in BRCA2 carriers that led to worse long-term OS. The gene discussed is BRCA2; the disease is breast carcinoma.